Clincosm LogoSign in Get a demo

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Sponsor
Tracon Pharmaceuticals Inc. (Industry)
Overall Status
No longer available
CT.gov ID
NCT02354612
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

Open-label, continuation study

Condition or Disease Intervention/Treatment Phase

Detailed Description

This is a multicenter, open-label, non-randomized, study of TRC105 in patients that have completed a previous TRC105 study and are judged by the investigator to have the potential to benefit from continued TRC105 therapy.

Study Design

Study Type:
Expanded Access
Official Title:
An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Participation in a TRACON Pharmaceuticals sponsored parent TRC105 study and, thought to have potential to derive clinical benefit from continued treatment with TRC105 in the opinion of the parent study investigator.

    • Willing and able to consent for self to participate in study

    • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

    • 18 years of age or older

    • ability to begin TRC105 dosing on this protocol within 6 weeks from the subjects last dose of TRC105 in the parent TRC105 study

    Exclusion Criteria:

    • Any clinical event that would make TRC105 therapy inappropriate under the parent protocol

    • Current treatment in another clinical study

    • Pregnant or breastfeeding

    • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator, would make the subject inappropriate for entry into the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UCLA Santa Monica California United States 90404

    Sponsors and Collaborators

    • Tracon Pharmaceuticals Inc.

    Investigators

    • Study Director: Charles Theuer, MD, Tracon Pharmaceuticals Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Tracon Pharmaceuticals Inc.
    ClinicalTrials.gov Identifier:
    NCT02354612
    Other Study ID Numbers:
    • 105CON101
    First Posted:
    Feb 3, 2015
    Last Update Posted:
    Feb 15, 2021
    Last Verified:
    Jan 1, 2021
    Additional relevant MeSH terms:
    Bevacizumab
    Capecitabine
    Axitinib

    Study Results

    No Results Posted as of Feb 15, 2021